China

CARsgen Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiri...

Lead Product(s): 7×21 CAR-T cells

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 17, 2020

Details:

Study results indicated the 7×21 CAR-T cells significantly outperformed the conventional CAR-T cells in cell proliferation and chemotaxis.

ImmVira

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Intratumoral Oncolytic Virus Imm...

Lead Product(s): oHSV-1

Therapeutic Area: Oncology Product Name: MVR-T3011

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Shanghai Pharma

Deal Size: $170.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 06, 2020

Details:

The license agreement is focused on ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.

I-Mab Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program

Lead Product(s): TJ-CD4B

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 12, 2020

Details:

The pre-clinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-Mab’s bispecific antibody portfolio, reflecting Company’s discovery and CMC capabilities to engineer novel molecules with combined target specificities.

Ascentage Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting

Lead Product(s): APG-3526

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

Ascentage Pharma will report six research results involving multiple cancer types in poster presentations during the meeting. Among them, APG-3526, the company's newest drug candidate, will be presented for the first time.

Innovent Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China

Lead Product(s): Anti-SIRP-alpha antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Alector

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 26, 2020

Details:

Under the agreement, Innovent will lead the development and commercialization of the molecule in China, including the manufacturing of the product.

Levena Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Navrogen and Levena collaborate to Develop Antibody Drug Conjugates

Lead Product(s): Antibody drug conjugates

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Navrogen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 04, 2020

Details:

ADCs developed under this collaboration combine Levena’s linker and cytotoxic payload chemistry expertise along with Navrogen’s cancer-targeting antibodies.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

CARsgen Therapeutics

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiri...

ImmVira

ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Intratumoral Oncolytic Virus Imm...

I-Mab Biopharma

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program

Ascentage Pharma

Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting

Innovent Biologics

Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China

Levena Biopharma

Navrogen and Levena collaborate to Develop Antibody Drug Conjugates